MX2020010259A - Preparacion farmaceutica. - Google Patents

Preparacion farmaceutica.

Info

Publication number
MX2020010259A
MX2020010259A MX2020010259A MX2020010259A MX2020010259A MX 2020010259 A MX2020010259 A MX 2020010259A MX 2020010259 A MX2020010259 A MX 2020010259A MX 2020010259 A MX2020010259 A MX 2020010259A MX 2020010259 A MX2020010259 A MX 2020010259A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
provides
present
preparation
rosuvastatin
Prior art date
Application number
MX2020010259A
Other languages
English (en)
Inventor
Sang Yeop Kim
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of MX2020010259A publication Critical patent/MX2020010259A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una preparación que contiene fimasartán, amlodipino y rosuvastatina como principios activos. La presente invención proporciona una preparación que tiene una excelente velocidad de disolución para cada principio activo y una alta estabilidad, permitiendo de este modo mejorar notablemente la conveniencia de la administración.
MX2020010259A 2018-04-30 2019-04-29 Preparacion farmaceutica. MX2020010259A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180050277A KR101992400B1 (ko) 2018-04-30 2018-04-30 약학적 제제
PCT/KR2019/005151 WO2019212214A1 (ko) 2018-04-30 2019-04-29 약학적 제제

Publications (1)

Publication Number Publication Date
MX2020010259A true MX2020010259A (es) 2020-10-22

Family

ID=67055715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010259A MX2020010259A (es) 2018-04-30 2019-04-29 Preparacion farmaceutica.

Country Status (9)

Country Link
KR (1) KR101992400B1 (es)
CN (1) CN112040933A (es)
MX (1) MX2020010259A (es)
PH (1) PH12020551547A1 (es)
RU (1) RU2756452C1 (es)
SG (1) SG11202009187YA (es)
TW (1) TWI697339B (es)
WO (1) WO2019212214A1 (es)
ZA (1) ZA202006346B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022260439A1 (ko) * 2021-06-09 2022-12-15 주식회사 보령 약학적 복합 제제 및 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336922A (zh) * 2008-08-08 2009-01-07 青岛黄海制药有限责任公司 一种瑞舒伐他汀氨氯地平组合物
PT2498758T (pt) * 2009-11-13 2018-10-23 Astrazeneca Uk Ltd Formulações de comprimido bicamada
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
KR101168136B1 (ko) * 2011-08-08 2012-07-24 보령제약 주식회사 혈압 강하용 약제학적 조성물
SG10201502582PA (en) * 2012-03-30 2015-05-28 Dae Woong Pharma Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
CN103156842B (zh) * 2013-03-08 2014-05-28 南开大学 牛蒡子苷元在制备抗心律失常药物中的用途
JP6068765B2 (ja) * 2013-03-14 2017-01-25 ボリュン ファーマスーティカル カンパニー リミテッド 薬学的複合製剤
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
HUE055181T2 (hu) * 2015-07-08 2021-11-29 Hk Inno N Corp Amlodipint, valsartant és rosuvastatint tartalmazó gyógyászati készítmény
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염

Also Published As

Publication number Publication date
TWI697339B (zh) 2020-07-01
TW201946916A (zh) 2019-12-16
ZA202006346B (en) 2022-01-26
PH12020551547A1 (en) 2021-06-07
WO2019212214A1 (ko) 2019-11-07
SG11202009187YA (en) 2020-10-29
KR101992400B1 (ko) 2019-06-24
CN112040933A (zh) 2020-12-04
RU2756452C1 (ru) 2021-09-30

Similar Documents

Publication Publication Date Title
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
EA201792591A1 (ru) Фармацевтические препараты
NZ764304A (en) Novel bradykinin b2 receptor antagonists
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
PH12020551547A1 (en) Pharmaceutical preparation
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
MX2021000769A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2020006886A (es) Sistema para suministro de medicamento.
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
MX2017014725A (es) Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.
PH12019501049A1 (en) Pharmaceutical composition containing palonosetron as active ingredient